Human Insulin Market Poised for Significant Growth Amid Healthcare Advancements

Trishita Deb
Trishita Deb

Updated · May 30, 2024

SHARE:

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Introduction

The Global Human Insulin Market, valued at USD 29.2 billion in 2023, is projected to witness substantial growth, reaching an estimated value of USD 46.7 billion by 2033. This growth trajectory is driven by a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period from 2024 to 2033.

The rapidly growing diabetic population across the globe is anticipated to propel the adoption of human insulin, which in turn is driving the market growth. The increasing prevalence of diabetes due to the higher adoption of a sedentary lifestyle is projected to propel the insulin market. Combined with this, favorable reimbursement policies in developed countries are estimated to boost the overall market.

The emergence of COVID-19 has impeded the demand for insulin due to fewer patients opted for the treatment of diabetes. In addition, key players operating in the market recorded a significant decline in their revenues due to the COVID-19 pandemic. The decline in the volume of diabetes testing and less focus on disease management other than COVID-19 and other major parameters affected insulin sales, especially during the first half of 2020. In terms of revenue, the market witnessed a decline of 5.5% in 2020.

However, revoking lockdown restrictions and stay-at-home orders in many countries, along with launches of novel drugs, and re-establishment of the supply chain network have been instrumental for the recovery during 2021. Novo Nordisk A/S insulin products revenue recovered by 4.3% compared to 2020. In addition, the revenues generated by Sanofi in 2021 increased 1.7% compared to the revenues in 2020. Therefore, the resumption of diabetes testing & new launches positively affected the demand for human insulin in 2021.

Human Insulin Market Size

To learn more about this report – request a sample report PDF

Key Takeaways

  • Market Size: The Human Insulin Market is projected to reach approximately USD 46.7 Billion by 2033, up from USD 29.2 Billion in 2023, indicating substantial growth potential.
  • Market Growth: Anticipated growth at a Compound Annual Growth Rate (CAGR) of 4.8% from 2024 to 2033 reflects sustained expansion within the market.
  • Type Analysis: Analog Human Insulin holds a significant market share, dominating the segment at 63.5% compared to Traditional Human Insulin.
  • Application Analysis: Diabetes Type 1 segment leads the market, accounting for 59.7% market share in 2023, driven by increasing prevalence and daily insulin requirements for blood glucose control.
  • Distribution Channel Analysis: Hospital pharmacies play a crucial role, capturing 60.5% market share, emphasizing their importance in ensuring accessibility to insulin products.
  • Regional Analysis: North America dominates with 40.7% market share, generating USD 11.8 billion in revenue. However, Asia Pacific is poised for the highest CAGR due to a substantial population at risk of diabetes.
  • Drivers: Launch of novel insulin products, rising geriatric population, and increasing demand for insulin are primary factors fueling market growth.
  • Restraints: Lack of health funding and diagnosis, particularly in emerging and developing regions, inhibits market growth. Additionally, expensive diagnostics treatments pose challenges, limiting accessibility to insulin.
  • Opportunities: Increasing investments in healthcare infrastructure, particularly in emerging economies, present growth opportunities for the human insulin market.
  • Trends: Lifestyle factors contributing to the rise in diabetes prevalence, coupled with improvements in research and healthcare facilities, are driving market growth. Furthermore, advancements in insulin delivery devices enhance patient convenience and safety.

Human Insulin Statistics

  • Global Diabetes Statistics: Approximately 537 million adults (20-79 years) are living with diabetes, according to the International Diabetes Federation.
  • Type 1 Diabetes in U.S.A: Approximately 1.6 million Americans have type 1 diabetes, including 187,000 children and adolescents​
  • Type 1 Diabetes Prevalence: There are about 9 million people worldwide with type 1 diabetes, who rely on daily insulin injections​..
  • Type 2 Diabetes Statistics: More than 60 million people with type 2 diabetes require insulin for managing their condition​.
  • Impact of COVID-19: Insulin demand dropped during the initial phase of the COVID-19 pandemic, with market revenues declining by 5.5% in 2020 due to fewer diabetes treatments​..
  • Insulin Price Cap in the US: The Inflation Reduction Act introduced a $ 35 monthly cap on insulin for Medicare beneficiaries starting January 2023, potentially saving seniors an average of $ 500 annually.
  • Insulin Manufacturers: Major companies like Eli Lilly have responded to policy changes by lowering their insulin prices by 70% and capping out-of-pocket costs at $35
  • Insulin Affordability Impact: The $ 35 cap would have saved 1.5 million Medicare beneficiaries around USD 734 million in 2020 if it had been in effect then.
  • Healthcare Spending: The U.S. spends around USD 237 billion annually on direct medical costs for diabetes​
  • Regional Market Leader: North America holds the largest market share, driven by high diabetes prevalence and advanced healthcare infrastructure​.
  • Projected Growth in Asia-Pacific: The Asia-Pacific region is expected to exhibit the highest growth rate due to increasing diabetes cases and improving healthcare facilities​.
  • State Savings Example: In California, the cost cap is projected to benefit 108,000 Medicare beneficiaries, saving them a total of approximately $36.6 million annually​.
  • Insulin Manufacturers: Three multinational companies control over 90% of the global insulin market, creating challenges for smaller manufacturers to compete​​.
  • Government and WHO Initiatives: WHO and various governments are working to improve insulin access through policy changes, price regulation, and promoting biosimilar insulin production​.
  • Technological Advancements: Innovations in insulin delivery systems, such as insulin pens and pumps, are enhancing the efficiency and convenience of insulin administration​.
  • Global Insulin Consumption: Despite the high prevalence of diabetes in low- and middle-income countries, these regions account for less than 40% of global insulin sales revenue​.

Emerging Trends

  • Technological Advancements: There is a significant focus on developing advanced insulin delivery systems, such as smart insulin pens and continuous glucose monitoring systems, which improve the accuracy and convenience of insulin administration.
  • Biosimilar Insulins: The production and approval of biosimilar insulins are increasing, providing more affordable options compared to brand-name insulin products. This trend aims to reduce the financial burden on patients and healthcare systems.
  • Government Policies: In the United States, the Inflation Reduction Act has introduced a $35 monthly cap on insulin for Medicare beneficiaries, which is expected to save seniors an average of $500 annually on insulin costs. This policy went into effect in January 2023 for Medicare Part D and in July 2023 for Medicare Part B.
  • Increasing Diabetes Prevalence: The prevalence of diabetes continues to rise, with approximately 34.2 million Americans diagnosed with the condition as of 2023. This growing patient population drives the demand for insulin.
  • Focus on Affordability: Efforts are being made to regulate insulin prices and reduce out-of-pocket costs for patients. This includes initiatives to make biosimilar insulins more accessible and affordable.
  • Global Health Initiatives: The World Health Organization (WHO) is working with countries and manufacturers to improve access to insulin, especially in low- and middle-income countries. These efforts include enhancing local production and distribution capabilities.
  • Integration of Digital Health: The integration of digital health technologies, such as mobile apps and telehealth services, is improving diabetes management and patient adherence to insulin therapy.
  • Research and Development: Ongoing research aims to develop new insulin formulations with improved pharmacokinetics and delivery methods. This includes ultra-rapid-acting insulins and insulins with longer duration of action.
  • Patient Education and Support: There is an increasing emphasis on patient education and support programs to ensure proper insulin usage and adherence to treatment plans. This helps improve patient outcomes and quality of life.
  • Collaborative Efforts: Partnerships between government agencies, healthcare providers, and pharmaceutical companies are crucial in addressing the challenges of insulin accessibility and affordability. These collaborations aim to streamline supply chains and enhance distribution networks.

Use Cases

Managing Type 1 Diabetes

  • Human insulin is essential for individuals with type 1 diabetes, as their bodies do not produce insulin. It helps maintain normal blood glucose levels, preventing severe complications.
  • More than 1.6 million Americans have type 1 diabetes, and insulin therapy is crucial for their survival.

Treating Type 2 Diabetes

  • For many with type 2 diabetes, insulin is used when other medications cannot maintain adequate blood glucose levels. It helps prevent long-term complications such as kidney damage and vision loss.
  • Over 30 million people in the U.S. have diabetes, with insulin being a key treatment for those with severe cases.

Use in Insulin Pumps

  • Insulin pumps deliver continuous insulin doses, offering precise control over blood sugar levels. This method is especially beneficial for those who struggle with frequent injections.
  • Pumps can reduce HbA1c levels significantly and improve quality of life for users.

Emergency Situations

  • In cases of diabetic ketoacidosis, a serious condition caused by very high blood sugar, rapid-acting human insulin can quickly lower glucose levels and stabilize the patient.
  • Nearly 200,000 cases of diabetic ketoacidosis are reported annually in the U.S.

Artificial Pancreas Systems

  • Advanced systems combine continuous glucose monitoring with insulin pumps to automatically regulate blood sugar, mimicking a healthy pancreas.
  • These systems can improve glucose control and reduce the burden of diabetes management.

Conclusion

The Human Insulin Market is poised for significant growth, driven by factors such as the rising diabetic population globally and favorable reimbursement policies. Despite initial setbacks due to the COVID-19 pandemic, the market has shown resilience with the revival of demand and the introduction of novel drugs. Key players like Novo Nordisk A/S and Sanofi have witnessed revenue recovery, signaling a positive outlook. With increasing investments in healthcare infrastructure and technological advancements in insulin delivery systems, the market presents lucrative opportunities for growth. However, challenges related to healthcare funding and accessibility remain, underscoring the need for continued focus on affordability and innovation.

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.